Clinical Disorder Treatment Market Segmentation by Drug Class (Antidepressants, Anticonvulsants, Anxiolytics, Atypical Antipsychotics, and Noradrenergic Agents); by Indication (Anxiety, and Depression); and by Drug Distribution Channel (Hospital, Retail, and Online Pharmacy) – Global Demand Analysis & Opportunity Outlook 2030
Buy Now
In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
May 2021- VistaGen Therapeutics announced the initiation of its PALISADE Phase-3 clinical program to test the efficacy and safety of PH94B for the acute treatment of social anxiety disorder among adults.
November 2020- Janssen Pharmaceuticals, a company of Johnson & Johnson, collaborated with Koa Health to research ways for pairing the delivery of digital cognitive behavioral therapy with pharmacological treatments to help patients with major depressive disorder.
The global clinical disorder treatment market is estimated to garner a sizeable revenue and grow at a CAGR of ~6% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence of psychiatric and psychological disorders, and rising cases of substance abuse among adolescents around the world. According to a statistical report titled Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), as of 2017, 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. Along with these, mounting need for effective management of anxiety and depression related disorders is also expected to drive market growth in the coming years. Furthermore, many hospitals, clinics and health institutions are organizing campaigns to create awareness about relevant treatment options for clinical disorders among general public. This in turn is projected to offer abundant growth opportunities to the market in the near future.
Get more information on this report: Download Sample PDF
The market is segmented by drug class into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents, out of which, the antidepressants segment is anticipated to hold the largest share in the global clinical disorder treatment market. This can be accounted to the high efficacy rate of antidepressants in lowering an individual’s depressive state of mind as compared to other available medications. Apart from these, increasing number of pipeline candidates and product approvals of antidepressants is also predicted to boost the market segment growth in the future. Additionally, on the basis of drug distribution channel, the hospital pharmacy segment is assessed to acquire the largest share during the forecast period owing to the increasing patient visits in hospitals, and high preference of patients to get treatment from hospitals.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global clinical disorder treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing incidences of substance abuse among teenagers and adults, especially in India and China, and increasing prevalence of clinical disorders in the region. In 2019, approximately 30 million people in South Asia admitted to using cannabis. Along with this, 22 million people consumed opioids in the region that year. Moreover, the market in North America is projected to acquire the largest share during the forecast period ascribing to the rising awareness levels about the symptoms of clinical disorders, and high healthcare spending in the region. In addition, strong presence of prominent market players is also expected to propel the market growth in the region in the coming years.
Get more information on this report: Download Sample PDF
The global clinical disorder treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global clinical disorder treatment market includes the following segments:
Ans: The major factors driving market growth are increasing prevalence of psychiatric and psychological disorders, and rising cases of substance abuse among adolescents worldwide.
Ans: The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2030.
Ans: Adverse effects of high drug dosage are estimated to hamper the market growth.
Ans: Asia Pacific will provide more business opportunities for market growth owing to the growing incidents of substance abuse among teenagers, especially in India and China, and increasing prevalence of clinical disorders in the region.
Ans: The major players in the market are Universal Health Services, Inc., CareTech Holdings PLC, Behavioral Health Network, Inc., Pfizer Inc., and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by drug class, indication, drug distribution channel, and by region.
Ans: The antidepressants segment is anticipated to hold largest market size in value and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample
